Dabigatran etexilate for secondary stroke prevention: the first year experience from a multicenter short-term registry
Discussion:
Our pilot data indicate that dabigatran appears to be safe for secondary stroke prevention during the first year of implementation of this therapy. However, high cost may limit the long-term treatment of AF patients with dabigatran, leading to early discontinuation.
Source: Therapeutic Advances in Neurological Disorders - Category: Neurology Authors: Tsivgoulis, G., Krogias, C., Sands, K. A., Sharma, V. K., Katsanos, A. H., Vadikolias, K., Papageorgiou, S. G., Heliopoulos, I., Shiue, H., Mitsoglou, A., Liantinioti, C., Athanasiadis, D., Giannopoulos, S., Piperidou, C., Voumvourakis, K., Alexandrov, A. Tags: Original Research Source Type: research
More News: Atrial Fibrillation | Bleeding | Cardiology | Congestive Heart Failure | Diabetes | Diabetes Mellitus | Dyspepsia | Endocrinology | Gastroenterology | Heart | Heart Attack | Heart Failure | Hemorrhagic Stroke | Hospitals | Hypertension | Ischemic Stroke | Neurology | Pradaxa | Stroke | Study